1. Home
  2. RMBS vs IOVA Comparison

RMBS vs IOVA Comparison

Compare RMBS & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rambus Inc.

RMBS

Rambus Inc.

HOLD

Current Price

$92.27

Market Cap

8.0B

Sector

Technology

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.53

Market Cap

968.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMBS
IOVA
Founded
1990
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
968.6M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
RMBS
IOVA
Price
$92.27
$2.53
Analyst Decision
Strong Buy
Buy
Analyst Count
7
12
Target Price
$102.00
$10.45
AVG Volume (30 Days)
1.4M
10.2M
Earning Date
02-02-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
30.64
N/A
EPS
2.10
N/A
Revenue
$678,488,000.00
$250,425,000.00
Revenue This Year
$29.01
$60.94
Revenue Next Year
$16.02
$60.85
P/E Ratio
$43.12
N/A
Revenue Growth
31.05
175.62
52 Week Low
$40.12
$1.64
52 Week High
$114.55
$8.15

Technical Indicators

Market Signals
Indicator
RMBS
IOVA
Relative Strength Index (RSI) 43.78 61.10
Support Level $90.10 $2.08
Resistance Level $98.26 $2.32
Average True Range (ATR) 5.01 0.13
MACD -0.80 0.02
Stochastic Oscillator 14.38 86.54

Price Performance

Historical Comparison
RMBS
IOVA

About RMBS Rambus Inc.

Rambus Inc is a semiconductor solutions provider offering high-speed, high-security computer chips and Silicon intellectual property. The company's key products include memory interface chips, built for high speed and efficiency; silicon IP, providing high-speed memory and chip-to-chip connection technology; and architecture licenses, which allow customers to use portions of Rambus' patented inventions for their own digital electronics. The firm receives the majority of its revenue from the United States, Taiwan, Asia, Japan, and Singapore.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: